Pfizer Says Monthly GLP-1 Candidate Could Rival Tirzepatide on Weight Loss
Pfizer stock rises after beating Q2 estimates and raising its 2026 revenue guidance to up to $62.5B. Get the key earnings takeaways.
Share
Why It Matters
Pfizer made more money than expected and thinks it will earn even more next year, partly because it's working on a new weight-loss medicine that could be as good as competitors' medicines.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.